Skill Guide

Research literacy - ability to read, critique, and apply findings from clinical trials and digital therapeutics literature

Research literacy is the ability to systematically interpret, critically evaluate, and translate findings from clinical trials and digital therapeutics (DTx) literature into actionable insights for product development, regulatory strategy, and clinical integration.

This skill directly reduces product and investment risk by ensuring decisions are grounded in validated evidence, preventing costly missteps in R&D and market access. It is a core competency for roles in Medical Affairs, Clinical Development, and Health Economics, driving evidence-based value narratives that persuade regulators, payers, and providers.

1 Careers

1 Categories

9.2 Avg Demand

15% Avg AI Risk

How to Learn Research literacy - ability to read, critique, and apply findings from clinical trials and digital therapeutics literature

1. Master clinical trial fundamentals: learn the phases (I-IV), common designs (RCT, crossover), and key terminology (ITT, p-values, confidence intervals). 2. Understand core regulatory frameworks: familiarize yourself with the FDA's DTx guidance and the EU MDR classification for software. 3. Build a habit of using primary sources: practice reading abstracts from NEJM, JAMA, and the Journal of Medical Internet Research (JMIR) weekly.

1. Apply critical appraisal tools: use frameworks like CONSORT for reporting trials or the Cochrane Risk of Bias tool to evaluate study validity. 2. Engage with real datasets: practice analyzing publicly available datasets from ClinicalTrials.gov or DTx case studies (e.g., Pear Therapeutics' reSET). 3. Avoid common pitfalls: distinguish statistical significance from clinical significance, and scrutinize surrogate endpoints vs. hard clinical outcomes.

1. Conduct systematic evidence synthesis: lead or participate in a literature review for a specific DTx indication, mapping the evidence landscape. 2. Develop integrated evidence plans: create a strategy that aligns RCT data with real-world evidence (RWE) to support payer dossiers (e.g., AMNOG, ICER submissions). 3. Mentor junior team members: guide them through deconstructing a primary study, focusing on design limitations and generalizability.

Practice Projects

Beginner

Case Study/Exercise

Deconstructing a Landmark DTx RCT

Scenario

You are a new clinical scientist at a DTx startup. Your manager asks you to summarize the pivotal trial for a competitor's product (e.g., Akili Interactive's ENDEAVOR-Rx for ADHD) to inform your own trial design.

How to Execute

1. Locate the primary publication and any FDA summary documents. 2. Create a structured summary table covering: Population (N, inclusion/exclusion), Intervention & Control, Primary & Secondary Endpoints, Key Results (with effect sizes), and Adverse Events. 3. Write a one-paragraph critique noting one major strength and one limitation of the study design.

Intermediate

Case Study/Exercise

DTx Market Access Evidence Gap Analysis

Scenario

You are a Health Economics and Outcomes Research (HEOR) manager. Your DTx for insomnia has completed a Phase 2 RCT. You must prepare for a pre-submission meeting with a national payer.

How to Execute

1. Analyze the existing RCT evidence against the payer's value framework (e.g., NICE evidence standards). 2. Identify critical evidence gaps (e.g., lack of long-term durability data, missing patient-reported outcomes). 3. Draft a 2-page briefing document outlining your proposed real-world evidence generation plan (e.g., registry study, pragmatic trial) to address these gaps before formal submission.

Advanced

Case Study/Exercise

Strategic Literature Review for an Integrated Evidence Portfolio

Scenario

You are the VP of Clinical Development. Your company is launching a DTx for Major Depressive Disorder (MDD) and needs to build a comprehensive evidence portfolio for global regulatory and payer engagement.

How to Execute

1. Conduct a systematic literature review of DTx in MDD, categorizing evidence by trial phase, outcome measures, and patient subgroups. 2. Map the findings against your product's specific clinical and economic claims. 3. Present a strategic evidence roadmap that integrates upcoming Phase 3 RCT results with planned post-market studies and head-to-head comparisons against standard-of-care apps.

Tools & Frameworks

Critical Appraisal Frameworks

CONSORT Statement (for RCT reporting)Cochrane Risk of Bias Tool (RoB 2)GRADE Framework (for certainty of evidence)

Use CONSORT to check completeness of trial reporting. Apply RoB 2 to assess internal validity. Use GRADE when synthesizing multiple studies to judge the strength of recommendation for an intervention.

Data & Registry Platforms

ClinicalTrials.govEU Clinical Trials RegisterPubMed/MEDLINE with MeSH termsJAMA Network Open / JMIR

ClinicalTrials.gov is essential for tracking ongoing trials and accessing results. PubMed with structured MeSH searches ensures comprehensive literature retrieval. JMIR is a primary source for digital health and DTx-specific research.

Regulatory & HTA Guidelines

FDA Guidance on Clinical Decision Support & DTxEU MDR (Medical Device Regulation) for Software as a Medical DeviceNICE Evidence Standards Framework for Digital Health Technologies

These are non-negotiable reference documents for understanding the evidentiary thresholds required by major markets. They dictate the study designs and endpoints that will be accepted by regulators and payers.

Interview Questions

Answer Strategy

The question tests the ability to distinguish statistical from clinical significance and to critique endpoint validity. Use a structured framework: 1) Interpret the p-value and effect size (Cohen's d, odds ratio). 2) Evaluate the PRO's psychometric validation and clinical relevance (e.g., minimally important difference). 3) Assess the risk: small effect size may not translate to meaningful patient benefit or payer acceptance, signaling high development risk. Sample answer: 'I'd first calculate the effect size to quantify the magnitude. A small d (<0.2) may not meet the minimally important difference for patients. Then, I'd scrutinize the PRO's validation history; if it's not established in this population, the result's interpretability is limited. For our pipeline, this evidence suggests a high-risk asset with uncertain market access potential, unless we can demonstrate the effect is consistent in a larger Phase 3 with a validated endpoint.'

Answer Strategy

This behavioral question tests intellectual rigor, courage, and influence. Use the STAR method, focusing on the analytical process and professional impact. Sample answer: 'Situation: A pivotal trial for a DTx reported superior efficacy based on an ITT analysis. Task: I was tasked with the regulatory submission. Action: I performed a per-protocol analysis and found the treatment effect diminished significantly, suggesting the ITT result was driven by protocol deviations in the control arm. I presented this sensitivity analysis to the team, arguing the true effect was uncertain. Outcome: We conducted additional subgroup analyses and revised our claims in the FDA submission to be more precise, which was accepted during review and strengthened our credibility with the agency.'